Altium Capital Management LLC Buys New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Altium Capital Management LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 95,000 shares of the biopharmaceutical company's stock, valued at approximately $2,860,000. Altium Capital Management LLC owned approximately 0.06% of TG Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quadrant Capital Group LLC boosted its holdings in shares of TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 975 shares during the last quarter. Blue Trust Inc. increased its position in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC bought a new position in shares of TG Therapeutics in the fourth quarter worth about $75,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded up $0.88 during midday trading on Tuesday, hitting $37.85. The company had a trading volume of 812,726 shares, compared to its average volume of 3,096,722. The stock has a market cap of $5.94 billion, a price-to-earnings ratio of -378.51 and a beta of 2.14. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a fifty day simple moving average of $36.46 and a 200 day simple moving average of $32.09.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. As a group, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on TGTX shares. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.